Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

787

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

DRUG: Placebo
DRUG: Nemolizumab

Sponsor

Galderma R&D